Abstrak 
Diabetes Mellitus and Tuberculosis Treatment
Rovina Ruslami, Reinout van Crevel
Universitas Padjadjaran, Karger, 2011, vol 40, pp 203-212, Antituberculosis Chemotherapy Volume Editors Peter R. Donald Tygerberg Paul D. van Helden Tygerberg 53 figures, 2 in color, 50 tables, 2011 Donald PR, van Heiden PD (eds): Antituberculosis Chemotherapy. Prog Respir Res. Basel
Bahasa Inggris
Universitas Padjadjaran, Karger, 2011, vol 40, pp 203-212, Antituberculosis Chemotherapy Volume Editors Peter R. Donald Tygerberg Paul D. van Helden Tygerberg 53 figures, 2 in color, 50 tables, 2011 Donald PR, van Heiden PD (eds): Antituberculosis Chemotherapy. Prog Respir Res. Basel
Diabetes Mellitus, tuberculosis
Diabetes mellitus (DM) not only increases the risk of active tuber¬culosis (TB) 3- to 5-fold, it also puts patients at an increased risk for poor treatment outcomes.The global epidemic of DM thus has seri¬ous implications for control and treatment of TB. DM in TB patients often goes unnoticed, but as many as 10-30% of TB patients may have concurrent DM. With regard to treatment, rifampicin ham¬pers glycaemic control by increasing the metabolism of most oral antidiabetic drugs, while DM has been associated with failure of TB treatment. Some data suggest that plasma rifampicin concen¬trations are lower in patients with DM. Although sometimes advo¬cated, TB prophylaxis has not been implemented widely among patients with DM. Prospective studies are needed to improve pre¬vention, early detection and treatment of concomitant DM and TB, especially in developing countries.